Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomePreferred Dividend PaymentsProfit After TaxResearch & DevelopmentSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Aptevo Therapeutics (APVO) EBIT (2016 - 2025)

Aptevo Therapeutics' EBIT history spans 11 years, with the latest figure at -$7.6 million for Q3 2025.

  • For Q3 2025, EBIT fell 45.98% year-over-year to -$7.6 million; the TTM value through Sep 2025 reached -$26.7 million, down 8.52%, while the annual FY2024 figure was -$24.6 million, 14.81% up from the prior year.
  • EBIT for Q3 2025 was -$7.6 million at Aptevo Therapeutics, down from -$6.2 million in the prior quarter.
  • Across five years, EBIT topped out at -$4.0 million in Q4 2021 and bottomed at -$8.2 million in Q2 2023.
  • The 5-year median for EBIT is -$6.5 million (2025), against an average of -$6.5 million.
  • The largest annual shift saw EBIT soared 40.75% in 2021 before it crashed 90.2% in 2022.
  • A 5-year view of EBIT shows it stood at -$4.0 million in 2021, then plummeted by 90.2% to -$7.7 million in 2022, then grew by 16.93% to -$6.4 million in 2023, then increased by 0.02% to -$6.4 million in 2024, then decreased by 19.24% to -$7.6 million in 2025.
  • Per Business Quant, the three most recent readings for APVO's EBIT are -$7.6 million (Q3 2025), -$6.2 million (Q2 2025), and -$6.5 million (Q1 2025).